Earnings Call
May 7, 2026
Q1 FY2026
EPS Estimate
-0.90
EPS Actual
-0.76
Post-Earnings Close
$105.00
Earnings Reaction
-23.4%
BRINSUPRI's first full calendar quarter as a commercial product delivered $305 million in net revenues, a 44% sequential increase off an already elevated Q4 2025 base, placing the launch on a trajectory that management argues is outpacing every meaningful specialty respiratory analog, including WINREVAIR and Rezdiffra in their respective first calendar Q1s. The result is particularly notable because Q1 is structurally the weakest quarter for specialty drug launches due to insurance plan resets, out-of-pocket cost resets, and reauthorization dynamics. Insmed reiterated full-year BRINSUPRI guidance of at least $1 billion in global net revenues, a target that, if achieved, would rank among the most successful drug launches in biotech history.
Report generated on May 8, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full INSM analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.